Bristol-Myers Squibb (BMY) to Release Quarterly Earnings on Monday

Bristol-Myers Squibb (NYSE:BMY) is scheduled to announce its earnings results before the market opens on Monday, February 5th. Analysts expect the company to announce earnings of $0.67 per share for the quarter.

Shares of Bristol-Myers Squibb (BMY) opened at $64.25 on Monday. The firm has a market cap of $105,160.00, a price-to-earnings ratio of 25.30, a price-to-earnings-growth ratio of 2.20 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb has a 12 month low of $47.12 and a 12 month high of $66.10.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.49%. Bristol-Myers Squibb’s payout ratio is currently 62.99%.

BMY has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price objective for the company in a research report on Wednesday, November 1st. SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Wednesday, October 25th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price objective for the company in a research report on Monday, October 9th. Finally, UBS Group reissued a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $65.38.

In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II bought 4,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

A number of institutional investors have recently modified their holdings of BMY. Renaissance Technologies LLC boosted its holdings in Bristol-Myers Squibb by 108.5% in the 2nd quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock worth $751,563,000 after buying an additional 7,020,200 shares during the period. Janus Henderson Group PLC boosted its holdings in Bristol-Myers Squibb by 2,990.5% in the 2nd quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock worth $202,494,000 after buying an additional 3,516,536 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Bristol-Myers Squibb by 42,071.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock worth $185,634,000 after buying an additional 3,323,649 shares during the period. Northern Trust Corp lifted its stake in Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after purchasing an additional 910,496 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Bristol-Myers Squibb by 28.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,747,541 shares of the biopharmaceutical company’s stock worth $208,815,000 after purchasing an additional 827,937 shares in the last quarter. 69.75% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb (BMY) to Release Quarterly Earnings on Monday” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/29/bristol-myers-squibb-bmy-to-release-quarterly-earnings-on-monday.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply